(Q41062805)

26 September 2017

1 reference

title

3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome (English)

1 reference

26 September 2017

1 reference

Molgó J

1

1 reference

26 September 2017

Guglielmi JM

series ordinal

2

1 reference

26 September 2017

publication date

1 January 1996

1 reference

26 September 2017

1 reference

26 September 2017

volume

431

1 reference

26 September 2017

issue

6 Suppl 2

1 reference

26 September 2017

page(s)

R295-6

1 reference

Guanidine and germine in Eaton-Lambert syndrome

26 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02346385

On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02346385

Guanidine and neuromuscular transmission. I. Effect on transmitter release occurring spontaneously and in response to single nerve stimuli

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02346385

The Lambert-Eaton myasthenic syndrome. A review of 50 cases

21 January 2018

1 reference

12 December 2020

Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

Short report: 4-Aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome

1 reference

12 December 2020

Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine

1 reference

12 December 2020

IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels

1 reference

12 December 2020

The mode of action of guanidine on mouse motor nerve terminals

1 reference

12 December 2020

Decreased calcium currents in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

Review of evidence for loss of motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity

1 reference

12 December 2020

Novel drug of choice in Eaton-Lambert syndrome

1 reference

12 December 2020

Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder

1 reference

12 December 2020

Potency of 3,4-Diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes

1 reference

12 December 2020

Lambert-Eaton myasthenic syndrome: pathogenesis and treatment

1 reference

12 December 2020

Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats

1 reference

12 December 2020

Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy

1 reference

12 December 2020

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis

1 reference

12 December 2020

Quantal components of end-plate potentials in the myasthenic syndrome

1 reference

12 December 2020

Changes in transmitter release at frog neuromuscular junction induced by 4-aminopyridine

1 reference

12 December 2020

Clinical, neurophysiological and morphological findings in Eaton Lambert syndrome

1 reference

12 December 2020

Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission

1 reference

12 December 2020

[Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine]

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02346385

1 reference

26 September 2017

1 reference